drugset / Trial / NCT03730311
Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers
RandomizedSequentialDouble-blindTreatment
Summary
A randomized, placebo-controlled, once weekly dose for four weeks, double blind study in Healthy HIV-Uninfected Volunteers. Each of 3 consequent groups (120 mg, 200 mg and 280mg) enrolls 6 active and 2 placebo subjects.
Timeline
- Start
- 2019-05
- Primary completion
- 2019-11
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elsulfavirine | Small molecule | 120 mg | Oral |
| Subject | Elsulfavirine | Small molecule | 200 mg | Oral |
| Subject | Elsulfavirine | Small molecule | 280 mg | Oral |